source
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.BioSpace · 7d ago↗ source
- 6 companies hiring in Cambridge nowLooking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.BioSpace · 7d ago↗ source
- US ‘eroding’ lead in rare diseases a matter of national security: ReportA Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allow…BioSpace · 7d ago